Belzutifan for von Hippel-Lindau disease with associated non-metastatic renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumours

Agency for Care Effectiveness (ACE)
Record ID 32018016078
English
Details
Project Status: Completed
Year Published: 2026
URL for published report: https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/-belzutifan-for-von-hippel-lindau-disease-with-associated-non-metastatic-renal-cell-carcinoma--central-nervous-system-hemangioblastomas--or-pancreatic-neuroendocrine-tumours-/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Singapore
MeSH Terms
  • von Hippel-Lindau Disease
  • Carcinoma, Renal Cell
  • Hemangioblastoma
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Antineoplastic Agents
  • Kidney Neoplasms
Contact
Organisation Name: Agency for Care Effectiveness (ACE)
Contact Address: Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name: ACE_HTA@moh.gov.sg
Contact Email: ACE_HTA@moh.gov.sg
Copyright: Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.